Related Experiment Video
Updated: Oct 12, 2025

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
Published on: December 15, 2023
Chronic Hepatitis B Infection Among Preexposure Prophylaxis Users Enrolled in a Population-Based Program in British
Kyle A Thompson1, Gabriel Blank2, Junine Toy1
1BC Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
Insights
Initiating pre-exposure prophylaxis (PrEP) for HIV also treats hepatitis B virus (HBV) infection. However, many patients in a Canadian PrEP program lacked necessary HBV DNA monitoring, highlighting a need for prescriber education.
Area of Science:
- Infectious Diseases
- Hepatology
- Public Health
Background:
- Hepatitis B virus (HBV) infection is a significant global health concern.
- Pre-exposure prophylaxis (PrEP) is a critical tool for human immunodeficiency virus (HIV) prevention.
- Certain antiretroviral medications used in PrEP have demonstrated activity against HBV.
Purpose of the Study:
- To determine the prevalence of chronic hepatitis B virus (HBV) infection among individuals enrolling in a provincial pre-exposure prophylaxis (PrEP) program.
- To assess the adequacy of HBV DNA monitoring for patients with chronic HBV within the PrEP program.
- To identify educational needs for healthcare providers prescribing PrEP regarding HBV co-infection management.
Main Methods:
- Retrospective analysis of patient data from a provincial PrEP program in British Columbia, Canada.
- Calculation of the prevalence of chronic HBV infection among program enrollees.
- Review of medical records to determine the proportion of patients with chronic HBV who received HBV DNA monitoring.
Main Results:
- The prevalence of chronic HBV infection was 0.86% (41 out of 4760) among PrEP program participants.
- A significant proportion, 46.3%, of individuals with chronic HBV lacked follow-up HBV DNA monitoring.
- This indicates a gap in the management of HBV in this patient population.
Conclusions:
- Initiation of PrEP for HIV prevention can concurrently treat chronic HBV infection.
- There is a critical need for improved HBV-related education for healthcare providers who prescribe PrEP.
- Enhanced prescriber education is essential to ensure adequate HBV monitoring and management in individuals on PrEP.
Abstract:
Initiation of human immunodeficiency virus preexposure prophylaxis (PrEP) medications will also treat hepatitis B infection (HBV). The prevalence of chronic HBV was 0.86% (n=41/4760) among enrollees in a provincial PrEP program in British Columbia, Canada. Overall, 46.3% lacked follow-up HBV DNA monitoring, underscoring the need for HBV-related education for PrEP prescribers.
Related Concept Videos
Transmission-based Precautions I: Contact, Enteric, and Droplets
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

